Skip Nav

Contact Us

Chondrosarcoma CS Foundation, Inc.

Thank you for your interest in our company. Complete the form below to send us an email, or simply give us a call. We're looking forward to working with you.

  • 301-352-3042

    Author Archives for admin

    CS Warrior Shares His Journey with an IDH1 inhibitor, clinical name ivosidenib.

    September 19, 2020 12:06 am Published by Comments Off on CS Warrior Shares His Journey with an IDH1 inhibitor, clinical name ivosidenib.

    Hello my CS brothers and sisters! I wanted to tell you a story about my journey which might help some of you. Here are some details: –diagnosed in Feb 2017, Grade 1 pelvic CS, spread widely on and around the acetabulum. Offered a hemipelvectomy but refused. –May 2017 started proton radiation at what is now [...]


    Chondrosarcoma Foundation Hosts: Straight Talk About Chondrosarcoma.

    September 10, 2020 4:51 pm Published by Comments Off on Chondrosarcoma Foundation Hosts: Straight Talk About Chondrosarcoma.

    On Tuesday, November 17, 2020 from 7:30pm -8:30pm, the Chondrosarcoma CS Foundation, Inc. will host a virtual dialogue using the zoom platform to reach out to sarcoma experts, and oncologists as well as patients diagnosed with Chondrosarcoma and their family members. The forum is entitled: Straight Talk About Chondrosarcoma. This event will provide an opportunity [...]


    Another Clinical Trail to Treat Metastatic Sarcoma

    September 8, 2020 7:07 pm Published by Comments Off on Another Clinical Trail to Treat Metastatic Sarcoma

    Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas https://clinicaltrials.gov/ct2/show/NCT03715933?term=DR5+INBRX109&rank=1 Go to Arm Intervention/treatment Experimental: Dose Escalation INBRX-109 will be escalated (3+3 design) in subjects with locally advanced or metastatic solid tumors including sarcomas. Drug: INBRX-109 – multivalent DR5 agonist antibody The active ingredient of INBRX-109 is a [...]


    CS Warrior Shares his Success with Ivosidenib

    September 5, 2020 12:52 am Published by Comments Off on CS Warrior Shares his Success with Ivosidenib

    Hello my CS brothers and sisters! I wanted to tell you a story about my journey which might help some of you. Here are some details: –diagnosed in Feb 2017, Grade 1 pelvic CS, spread widely on and around the acetabulum. Offered a hemipelvectomy but refused. –May 2017 started proton radiation at what is now [...]


    More information on the Phase 2 Clinical Trail to Treat Conventional Chondrosarcoma

    September 3, 2020 6:30 pm Published by Comments Off on More information on the Phase 2 Clinical Trail to Treat Conventional Chondrosarcoma

    A CS Warrior on the Facebook Chondrosarcoma Support Group entered a new Phase 2 clinical trial yesterday specifically for unresectable and metastatic conventional CS that combines a histone deacetylase inhibitor Belinostat (FDA approved for a type of lymphoma) with an experimental DNA hypomethylating agent Guadecitabine (https://clinicaltrials.gov/ct2/show/study/NCT04340843). The study is currently recruiting at Columbia Medical Center [...]


    September is Childhood Cancer Awareness Month

    September 2, 2020 1:17 am Published by Comments Off on September is Childhood Cancer Awareness Month

    In September, we honor the gold ribbon in recognition of Childhood Cancer Awareness Month! ✨ Did you know cancer is the second leading cause of death in children under the age of 15? In 2020, approximately 11,000 children ages 1-14 will be diagnosed with cancer. Medical and technological advances, however, now provide that about 85% [...]


    A Clinical Trail for Unresectable and Metastatic Conventional Chondrosarcoma

    September 2, 2020 1:04 am Published by Comments Off on A Clinical Trail for Unresectable and Metastatic Conventional Chondrosarcoma

    Testing the Combination of Belinostat and SGI-110 (Guadecitabine) for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma clinicaltrials.gov Brief Summary: This phase II trial studies how well belinostat and SGI-110 (guadecitabine) work in treating patients with conventional chondrosarcoma that cannot be removed by surgery (unresectable) and has spread to other places in the body (metastatic). [...]


    The Hunt for Predictive Biomarkers to Treat Soft Tissue Sarcomas

    August 29, 2020 12:52 am Published by Comments Off on The Hunt for Predictive Biomarkers to Treat Soft Tissue Sarcomas

    Schwartz Hunts for Predictive Biomarkers in Soft Tissue Sarcoma Gary K. Schwartz, MD, highlights research that is being done with regard to genomic signatures in sarcoma, challenges faced with immunotherapy, and where the field is headed. Gary K. Schwartz, MD Although several research efforts have been dedicated to evaluating the use of immunotherapy in patients [...]


    Another Potential Medication to Treat Chondrosarcoma

    August 16, 2020 3:34 am Published by Comments Off on Another Potential Medication to Treat Chondrosarcoma

    Targeting the Multidrug Transporter Ptch1 Potentiates Chemotherapy Efficiency Abstract One of the crucial challenges in the clinical management of cancer is resistance to chemotherapeutics. Multidrug resistance (MDR) has been intensively studied, and one of the most prominent mechanisms underlying MDR is overexpression of adenosine triphosphate (ATP)-binding cassette (ABC) transporters. Despite research efforts to develop compounds [...]


    Skip to content